olivLaw · US equity research
RadNet, Inc. RDNT
Services-Medical Laboratories · SIC 8071 · Vertical: Services-Medical Laboratories (SIC 8071)
RadNet is the largest U.S. operator of freestanding outpatient diagnostic imaging centers and, through its Digital Health division, develops AI and radiology software. In 2026 the company is growing revenue and advanced imaging volumes, while its software segment is accelerating, which makes its trajectory relevant to the healthcare system. The company reported 442 centers at June 30, 2026, and total company revenue reached 622.7 million dollars in the second quarter of 2026.
At the close of 04 Nov 2026, RadNet, Inc. (RDNT) stock was 80.26 USD (+9.67% on the day), with market capitalisation 6.3 bn USD, beta 1.13, 52-week range 51.87–84.48 USD. Latest reported quarter (Q2 2026): revenue of 622.7 m USD (+25.0% YoY), net income of 7.5 m USD (−47.9% YoY), diluted EPS 0.10 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 72.7
- overbought (≥ 70)
- Bollinger (20, 2)
- 66.04 – 76.88
- above the upper band · %B 1.31 · band width 15.2%
- SMA 50 / 200
- 72.52 / 65.20
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 1.10 / 0.22
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +13.7% | −1.1% | +14.8 pp | — |
| 3 months | +19.7% | −0.5% | +20.1 pp | — |
| 6 months | +36.9% | +4.4% | +32.5 pp | — |
| Year to date | +12.5% | +12.3% | +0.2 pp | — |
| 1 year | +2.3% | +13.5% | −11.3 pp | +7.7% |
| 3 years | +178.3% | +76.4% | +101.9 pp | +62.1% |
| 5 years | +132.0% | +63.7% | +68.3 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 461.1 m | 477.1 m | 471.4 m | 498.2 m | 522.9 m | 547.7 m | 575.6 m | 622.7 m |
| Operating income | 33.9 m | 24.5 m | -24.1 m | 30.9 m | 27.4 m | 27.8 m | -23.9 m | 39.5 m |
| Depreciation & amortisation | 35.0 m | 36.0 m | 35.5 m | 36.0 m | 39.8 m | 40.9 m | 45.0 m | 45.5 m |
| Interest expense | 19.4 m | 18.1 m | 17.2 m | 17.2 m | 17.4 m | 18.1 m | 17.7 m | 18.2 m |
| Pre-tax income | 16.6 m | 15.3 m | -33.1 m | 23.9 m | 20.3 m | 20.9 m | -32.8 m | 26.6 m |
| Income tax | 4.3 m | 1.1 m | -3.4 m | 820.0 k | 6.4 m | 11.1 m | -8.1 m | 6.4 m |
| Net income | 3.2 m | 5.3 m | -37.9 m | 14.5 m | 5.4 m | -597.0 k | -33.5 m | 7.5 m |
| Diluted EPS | 0.04 | 0.07 ≈ | -0.51 | 0.19 | 0.07 | -0.01 ≈ | -0.43 | 0.10 |
| Operating cash flow | 57.4 m ≈ | 42.5 m | 41.5 m | 120.3 m ≈ | 52.8 m ≈ | 84.2 m | 79.0 m | 94.1 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 975.1 m | 1.2 bn | 1.1 bn | 1.3 bn | 1.4 bn | 1.6 bn | 1.8 bn | 2.0 bn |
| Revenue YoY | +5.7% | +18.4% | −7.1% | +22.7% | +8.7% | +13.0% | +13.2% | +11.5% |
| Net income | 32.2 m | 14.8 m | -14.8 m | 24.7 m | 10.7 m | 3.0 m | 2.8 m | -18.7 m |
| Net income YoY | +60,735.8% | −54.2% | −200.6% | unavailable | −56.9% | −71.4% | −8.2% | −767.8% |
| Diluted EPS | 0.66 | 0.29 | -0.29 | 0.46 | 0.17 | 0.05 | 0.04 | -0.25 |
| Diluted EPS YoY | unavailable | −56.1% | −200.0% | unavailable | −63.0% | −70.6% | −20.0% | −725.0% |
| net % | 3.3% | 1.3% | -1.4% | 1.9% | 0.7% | 0.2% | 0.2% | -0.9% |
| Free cash flow | 44.6 m | 30.2 m | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 767.2 m USD
- Financial debt
- 1.1 bn USD
- Net debt
- 322.7 m USD
- Equity
- 1.4 bn USD
- Total assets
- 3.8 bn USD
- Debt / equity
- 0.80x
- Current ratio
- 1.76x
- ROE
- -1.5%
- ROA
- -0.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.1 bn | 1.3 bn | 1.4 bn | 1.6 bn | 1.8 bn | 2.0 bn | SEC (XBRL)· 02 Mar 2026verified |
| Operating income | 35.7 m | 82.6 m | 46.4 m | 98.7 m | 104.6 m | 62.0 m | SEC (XBRL)· 02 Mar 2026verified |
| Depreciation & amortisation | 86.8 m | 96.7 m | 115.9 m | 128.4 m | 137.8 m | 152.1 m | SEC (XBRL)· 02 Mar 2026verified |
| EBITDA | 122.5 m ≈ | 179.2 m ≈ | 162.2 m ≈ | 227.1 m ≈ | 242.5 m ≈ | 214.1 m ≈ | SEC (XBRL)· 02 Mar 2026derived |
| Interest expense | 45.9 m | 48.8 m | 50.8 m | 64.5 m | 79.8 m | 69.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Pre-tax income | -854.0 k | 58.9 m | 43.0 m | 38.8 m | 44.9 m | 31.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Income tax | 895.0 k | 14.6 m | 9.4 m | 8.5 m | 6.0 m | 14.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Net income | -14.8 m | 24.7 m | 10.7 m | 3.0 m | 2.8 m | -18.7 m | SEC (XBRL)· 02 Mar 2026verified |
| Diluted EPS | -0.29 | 0.46 | 0.17 | 0.05 | 0.04 | -0.25 | SEC (XBRL)· 02 Mar 2026verified |
| Weighted average diluted shares | 50.9 m | 53.4 m | 57.3 m | 64.7 m | 74.8 m | 75.2 m | SEC (XBRL)· 02 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 102.0 m | 134.6 m | 127.8 m | 342.6 m | 740.0 m | 767.2 m | SEC (XBRL)· 02 Mar 2026verified |
| Receivables | 129.6 m | 135.1 m | 166.4 m | 163.7 m | 185.8 m | 200.3 m | SEC (XBRL)· 02 Mar 2026verified |
| Current assets | 270.4 m | 324.3 m | 367.2 m | 579.3 m | 1.0 bn | 1.0 bn | SEC (XBRL)· 02 Mar 2026verified |
| Property, plant & equipment, net | 399.3 m | 484.2 m | 566.0 m | 604.4 m | 694.8 m | 807.7 m | SEC (XBRL)· 02 Mar 2026verified |
| Goodwill | 472.9 m | 513.8 m | 677.7 m | 679.5 m | 710.7 m | 907.7 m | SEC (XBRL)· 02 Mar 2026verified |
| Intangibles (excl. goodwill) | 52.4 m | 56.6 m | 106.2 m | 90.6 m | 81.4 m | 148.5 m | SEC (XBRL)· 02 Mar 2026verified |
| Total assets | 1.8 bn | 2.1 bn | 2.4 bn | 2.7 bn | 3.3 bn | 3.8 bn | SEC (XBRL)· 02 Mar 2026verified |
| Accounts payable | 70.1 m | 86.5 m | 102.7 m | 122.9 m | 96.5 m | 153.2 m | SEC (XBRL)· 02 Mar 2026verified |
| Short-term debt | 39.8 m | 11.2 m | 12.4 m | 18.0 m | 24.7 m | 25.4 m | SEC (XBRL)· 02 Mar 2026verified |
| Long-term debt | 612.9 m | 743.5 m | 839.3 m | 812.1 m | 991.6 m | 1.1 bn | SEC (XBRL)· 02 Mar 2026verified |
| Current liabilities | 398.1 m | 374.8 m | 466.7 m | 437.5 m | 479.7 m | 586.8 m | SEC (XBRL)· 02 Mar 2026verified |
| Total liabilities | 1.5 bn | 1.7 bn | 1.9 bn | 1.9 bn | 2.2 bn | 2.4 bn | SEC (XBRL)· 02 Mar 2026verified |
| Equity | 258.3 m | 346.2 m | 491.5 m | 813.4 m | 1.1 bn | 1.4 bn | SEC (XBRL)· 02 Mar 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 233.8 m | 149.5 m | 146.4 m | 220.9 m | 233.0 m | 298.8 m | SEC (XBRL)· 02 Mar 2026verified |
| Investing cash flow | -126.2 m | -221.5 m | -246.9 m | -201.5 m | -233.1 m | -343.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Financing cash flow | -45.6 m | 104.7 m | 93.6 m | 195.6 m | 398.0 m | 72.2 m | SEC (XBRL)· 02 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 56.2% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 6.3 bn USD
Key indicators
Coverage and freshness
Score by group
56% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 38.81 – 43.69 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDA38.81 – 43.69 (Mid 40.66)4 companies used · median multiple 15.7x · quartiles 15.1x – 16.7xAMS, BLLN, DGX, LH
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 56.2% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 2.3% | 75 (vs peers) | 19% |
| Net margin · Quality | -0.9% | 70 (vs peers) | 11% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 12.6% | 100 (on a fixed band) | 15% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 2.5x | 60 (vs peers) | 19% |
| Interest coverage · Balance sheet | 1.0x | 0 (on a fixed band) | 11% |
| Current ratio · Balance sheet | 1.5x | 57 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | 28.6x | 20 (vs peers) | 19% |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet41/100 · 3/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality73/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial20/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
RadNet, Inc. (RDNT). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 2.0 bn USD in 2025; YoY growth 11.5%; net margin -0.9%; ROE -2.1%; net debt/EBITDA 2.5x.
The estimated value range is 38.81–43.69 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 40.66 USD, the price of 80.26 USD leaves a potential of -49.3% (value / price − 1) and a margin of safety of -97.4% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 56.2% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 2.3%
- Revenue CAGR 3Y: 12.6%
What contradicts it
- Interest coverage: 1.0x
- EV/EBITDA: 28.6x
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, P/E (TTM), FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Medical Laboratories (SIC 8071) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| NTRANatera, Inc. | 56.4 bn | — | -12.5% | -7.1% | +35.9% | +64% / +599% |
| LHLabcorp Holdings Inc. | 29.9 bn | 30.2 | 11.4% | 6.9% | +7.2% | +37% / +70% |
| DGXQuest Diagnostics Inc | 28.1 bn | 25.5 | 15.2% | 9.5% | +11.8% | +35% / +86% |
| GHGuardant Health, Inc. | 22.6 bn | — | — | -38.3% | +32.9% | +55% / +570% |
| CAICaris Life Sciences, Inc. | 9.5 bn | 97.6 | 17.2% | 9.2% | +97.0% | +30% / unavailable |
| GRALGRAIL, Inc. | 6.4 bn | — | -16.1% | -236.9% | +17.2% | +30% / unavailable |
| RDNTRadNet, Inc. | 6.3 bn | — | -2.1% | -0.9% | +11.5% | +2% / +178% |
| CDNACaredx, Inc. | 4.5 bn | 35.9 | 33.0% | 25.9% | +13.8% | +380% / +784% |
| VCYTVeracyte, Inc. | 4.2 bn | 37.5 | 8.8% | 20.4% | +16.0% | +11% / +105% |
| FTREFortrea Holdings Inc. | 2.0 bn | — | -12.3% | -2.6% | +1.0% | +64% / −29% |
| PSNLPersonalis, Inc. | 1.7 bn | — | -62.1% | -147.7% | −17.7% | +47% / +932% |
| BLLNBillionToOne, Inc. | 1.3 bn | 118.4 | 30.2% | 11.3% | +100.0% | −13% / unavailable |
| CSTLCastle Biosciences, Inc. | 1.1 bn | — | -4.2% | -5.4% | +3.7% | −11% / +79% |
| FLGTFulgent Genetics, Inc. | 541.5 m | — | -8.0% | -26.0% | +13.8% | −33% / −29% |
| YDESYD Bio Limited | 492.0 m | — | -445.1% | -1,392.6% | +16.9% | −40% / unavailable |
| BDSXBiodesix, Inc. | 226.7 m | — | -540.0% | -27.0% | +24.1% | +160% / −28% |
| XGNExagen Inc. | 206.2 m | — | -113.8% | -26.6% | +19.7% | +8% / +363% |
| SERASera Prognostics, Inc. | 59.0 m | — | -49.7% | -34,866.7% | +5.2% | −39% / +4% |
| AMSAmerican Shared Hospital Services | 8.2 m | — | -7.5% | -5.8% | −0.9% | −43% / −48% |
| MDXHMdxhealth SA | 8.0 m | — | -2,440.4% | -31.1% | +19.8% | −96% / −95% |
| ACONAclarion, Inc. | 5.0 m | — | -59.0% | -10,978.5% | +65.6% | −72% / −100% |
| ADVBAdvanced Biomed Inc. | 3.5 m | 0.4 | 84.8% | 5,231.3% | unavailable | −75% / unavailable |
| BGLCBioNexus Gene Lab Corp. | 2.8 m | — | -33.7% | -82.4% | −21.9% | −79% / −90% |
| BNRBurning Rock Biotech Limited | 0 | — | -10.1% | -10.3% | +9.2% | −41% / +55% |
1- and 3-year price returns: for RDNT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
RadNet is the largest U.S. operator of freestanding outpatient diagnostic imaging centers and, through its Digital Health division, develops AI and radiology software. In 2026 the company is growing revenue and advanced imaging volumes, while its software segment is accelerating, which makes its trajectory relevant to the healthcare system 123. The company reported 442 centers at June 30, 2026, and total company revenue reached 622.7 million dollars in the second quarter of 2026 23.
SWOT
Strengths
- The company is the largest U.S. operator of outpatient imaging centers, with a multi-modality network and a diversified payor base 1.
- Growth in advanced imaging and Digital Health revenue shows solid execution in recent quarters 23.
- Health system partnerships and integrated AI acquisitions strengthen its position in regional networks 23.
Weaknesses
- Digital Health profitability declined in the second quarter of 2026 because of staffing investments and integration costs 3.
- The company relies heavily on Medicare, Medicaid and commercial payor rates, which exposes it to changes in reimbursement 1.
- Debt and interest costs remain a burden, especially in a high-rate environment, although the leverage ratio is managed 13.
Opportunities
- If hospitals widely adopt DeepHealth solutions, Digital Health ARR could keep growing 23.
- New joint ventures and expansion into new states could add centers and procedure volumes 23.
- AI deployment in screening programs, for example breast cancer screening, could raise efficiency and service revenue 12.
Threats
- Medicare rate cuts and managed care pressure could compress margins per procedure 1.
- Competitors with greater financial resources could expand quickly and attract patients and referring physicians 1.
- An economic downturn or a health crisis could reduce demand for non-urgent procedures and affect payor payments 1.
Risks
- Lower reimbursementhigh
Cuts in Medicare or commercial plan rates could reduce revenue per procedure and operating margins 1.
- Labor costsmedium
Higher minimum wages and competition for qualified staff could raise costs if they cannot be passed on to payors 1.
- Debt and interest ratesmedium
Most debt carries variable rates, and high interest rates could raise financing costs 13.
- Integration of acquisitionsmedium
Integrating iCAD, See-Mode, CIMAR and Gleamer could be delayed or fail to deliver expected synergies 23.
- Natural disasterslow
Centers concentrated in California and on the East Coast are exposed to wildfires, earthquakes and storms that could interrupt operations 1.
Investment thesis
What would need to be true (bull case)
- If the growth in advanced imaging and software revenue persists, the company could keep improving its margins and revenue mix 23.
- Growth in Digital Health ARR could turn the segment into a larger share of recurring revenue 23.
- An aging population and expanded screening could support long-term demand for multi-modality centers 1.
What would break the thesis
What to watch
- Development of Digital Health ARR and segment marginQ3 2026
- Integration of Gleamer and rollout of the breast ultrasound AI solution across RadNet centersQ3 2026
- Revised guidance for revenue and adjusted EBITDA in the Imaging Centers segment2026
- Changes to Medicare reimbursement rates and the effects of new regulationnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
RadNet, Inc. (NASDAQ: RDNT) is a national provider of diagnostic imaging services in the United States, in business since 1985, with 418 centers at year-end 2025 1. The Imaging Centers segment offers MRI, CT, PET, nuclear medicine, mammography, ultrasound, X-ray and fluoroscopy, and most centers are multi-modality 1. Consolidated revenue was 2040.2 million dollars in 2025 1.
The company also operates through joint ventures with hospitals and health systems, and at June 30, 2026 about 36% of its 442 locations were in such partnerships 23. In the United Kingdom, the subsidiary HLH Imaging provides teleradiology services within the National Health Service 12.
The Digital Health division, branded DeepHealth, combines AI and radiology informatics, including the DeepHealth OS cloud operating system, and has been extended through acquisitions such as iCAD, See-Mode, CIMAR and Gleamer 12. Segment revenue rose 56.5% in the second quarter of 2026 3.
Segments
Market context
The U.S. diagnostic imaging market is growing, supported by an aging population: about 62 million Americans were over 65, or 18% of the population 1. Demand for MRI and CT, the fastest-growing and higher-margin modalities, is also supported by preventive screening and new clinical applications 1.
In AI software, the U.S. Food & Drug Administration had cleared over 700 AI and machine learning radiology products by August 2024, which points to a competitive and expanding market 1.
Trends
- Growth in advanced imagingtailwind
MRI, CT and PET/CT volumes are growing faster than routine imaging, which improves revenue mix and center margins if the trend holds 13.
- Adoption of AI in radiologytailwind
AI tools are increasingly used for diagnosis and workflow efficiency, which could generate new revenue for Digital Health if hospitals adopt them widely 12.
- Pressure on reimbursement ratesheadwind
Medicare rate reductions and managed care pressure could reduce revenue per procedure if such measures expand 1.
- Rising labor costsheadwind
Minimum wage increases in some states, including California, raise operating costs, and the company may not be able to pass them fully to payors 1.
Competitive position
Competition comes from independent imaging operators, private equity-backed chains, smaller regional operators, and hospitals or radiology groups with their own equipment 1. Some competitors could have greater financial resources, allowing them to open more centers 1.
The company differentiates itself through scale, dense regional networks and multi-modality offerings, which let it charge generally lower fees than hospitals for the same services 1.
- Independent imaging operators
Independent and regional operators competing directly in the same local outpatient markets.
- Private equity-backed imaging chains
Imaging center chains with financial resources that could fund rapid expansion.
- Hospitals and radiology groups
Hospitals and radiology groups with their own equipment are a direct alternative for patients and referring physicians.
- Radiology software providers
Companies offering AI and radiology informatics compete with the Digital Health division.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- RadNet (RDNT) Posts Record Revenue But Profit Growth LagsYahoo Finance — News · 04 Sept 2026 · EN
The latest news item in our archive is from 04 Sept 2026; the newest SEC filing is from 26 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report26 Oct 2026Material agreement · Item 3.02 · Regulation FD disclosure · Financial statements and exhibits
- Current report14 Aug 2026Other events · Financial statements and exhibits
- Quarterly report10 Aug 2026
- Current report10 Aug 2026Results of operations · Financial statements and exhibits
- Current report10 Jun 2026Material agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
- Current report04 Jun 2026Shareholder vote
- Current report03 Jun 2026Other events · Financial statements and exhibits
- Quarterly report11 May 2026
- Current report11 May 2026Results of operations · Financial statements and exhibits
- Proxy statement20 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / RadNet, Inc. · 02 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / RadNet, Inc. · 10 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / RadNet, Inc. · 10 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.